Dihydrotestosterone acetate
Dihydrotestosterone acetate (DHTA) is a synthetic androgen and anabolic steroid and a derivative of dihydrotestosterone (DHT). It is more commonly known as androstanolone acetate and stanolone acetate.
Chemistry[edit]
Dihydrotestosterone acetate, like all synthetic androgens and anabolic steroids, is derived from testosterone. It is specifically a derivative of DHT, which is itself a metabolite of testosterone. DHTA is formed by the addition of an acetyl group to the 17th carbon position of DHT. This modification increases the hormone's anabolic activity and reduces its androgenic potency.
Pharmacology[edit]
DHTA acts as a potent androgen receptor agonist. It has a high affinity for the androgen receptor and is believed to have a role in the development and maintenance of male secondary sexual characteristics. DHTA is also thought to have anabolic effects, promoting the growth and repair of muscle tissue.
Medical Uses[edit]
DHTA has been used in the treatment of conditions such as hypogonadism, a condition in which the body does not produce enough testosterone. It has also been used to treat certain forms of breast cancer in women. However, its use in these contexts is limited due to its potential for causing virilization (the development of male characteristics) in women and children.
Side Effects[edit]
The side effects of DHTA are similar to those of other androgens and anabolic steroids. These can include acne, hair loss, increased body hair growth, and changes in mood and behavior. More serious side effects can include liver damage, cardiovascular disease, and an increased risk of prostate cancer in men.
Legal Status[edit]
In many countries, including the United States, DHTA is classified as a controlled substance. This means that its use, possession, and distribution are regulated by law. In the U.S., it is classified as a Schedule III controlled substance under the Controlled Substances Act.
See Also[edit]
-
Dihydrotestosterone acetate chemical structure
-
Dihydrotestosterone acetate ball-and-stick model
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
